GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CMG Pharmaceutical Co 058820.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

3,820

-0.78%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CMG Pharmaceutical Co

Its shares trade on KOSDAQ under the ticker 058820.KQ. It has been listed since 31 August 2001. In the fiscal year to 31 December 2025, it reported revenue of ₩105.23bn and a net loss of ₩10.08bn. At that date it held total assets of ₩305.96bn and shareholders' equity of ₩201.55bn.

CMG Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-08-31. The Company’s products include antibiotics, antifungals, antivirus, anti-tuberculousis drugs, peptic ulcer drugs, dementia remedies, antihistamines and antipyretics, among others. The company is also engaged in the manufacture of stone products. The firm mainly distributes is pharmaceutical products within domestic markets, as well as to overseas markets. On April 16, 2013, the Company changed its name from SKYNEWPHARM. Co., Ltd to CMG Pharmaceutical Co., Ltd.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
31 Aug 2001
Employees
248

Leadership

Pay as last reported

  • Jeong Ho KimChief Executive Officer, Director, since 2014
  • Gyeong Wuk YoonVice President, Director
  • Yin Su ParkInternal Auditor
  • Jun Won ChoiDirector
  • Jong Guk SongDirector
  • Tae Gyu SonNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CMG Pharmaceutical Co. Ltd. produces antibiotics and antifungals for domestic markets.
  • The company's product range includes dementia remedies and antihistamines for global distribution.
  • CMG Pharmaceutical has 248 full-time employees supporting its pharmaceutical operations.

Weaknesses

  • CMG Pharmaceutical Co. Ltd. manufactures stone products alongside pharmaceuticals.
  • The company's primary focus is on domestic markets with limited overseas expansion.
  • CMG Pharmaceutical's product portfolio lacks antiviral drugs for pandemic preparedness.

Opportunities

  • The global demand for dementia remedies is increasing in the Health Care sector.
  • CMG Pharmaceutical can expand into antiviral drug manufacturing for new markets.
  • The company can leverage its 2001 IPO to attract international investors.

Threats

  • CMG Pharmaceutical's reliance on domestic markets exposes it to local economic fluctuations.
  • The company's stone product manufacturing may face regulatory challenges in the Health Care sector.
  • Competition in the pharmaceutical industry intensifies with new entrants in KR.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.